CH
ALNY icon

Cromwell Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cromwell Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Buy
43
+23
+115% +$6.94K 0.01% 598
2026
Q1 		$6.62K Hold
20
– – ﹤0.01% 604
2025
Q4 		$7.95K Hold
20
– – ﹤0.01% 598
2025
Q3 		$9.12K Hold
20
– – ﹤0.01% 615
2025
Q2 		$6.52K Buy
20
+14
+233% +$3.87K ﹤0.01% 613
2025
Q1 		$1.62K Buy
+6
New +$1.54K ﹤0.01% 621

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cromwell Holdings's ALNY Position: Q2 2026 in Review

Cromwell Holdings increased its Alnylam Pharmaceuticals (ALNY) stake by 115% in Q2 2026, buying an estimated $6.94K and bringing the position to 43 shares worth $12.9K. The position accounts for 0.01% of the portfolio, ranked #598.

Cromwell Holdings first reported a position in ALNY in Q1 2025 and has held it in 6 quarters since. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Cromwell Holdings held 43 shares of Alnylam Pharmaceuticals worth $12.9K as of Q2 2026.
  • Cromwell Holdings bought 23 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $6.94K.
  • Alnylam Pharmaceuticals made up 0.01% of Cromwell Holdings's portfolio in Q2 2026, its #598 holding.
  • Cromwell Holdings first reported a position in Alnylam Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Cromwell Holdings's 13F filing for Q2 2026, filed 14 Jul 2026.